Sasko Kedev
Sasko Kedev is an expert in Cardiology at University of Ss. Cyril and Methodius in Trnava (Slovakia). As of September 2026, ScienceLeadR ranks Sasko Kedev in the top 1% of experts worldwide for Myocardial Ischemia, and in the top 1% of experts in Slovakia for Coronary Disease and Arterial Occlusive Diseases. Sasko Kedev has authored 300 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 2 of them ongoing. SLR score: 991 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Biostatistics - Medical Imaging
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 300
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial. PMID 42384892 — exercise, myocardial ischemia, research design, exercise tolerance, laboratories, stress, physiological, odds ratio, echocardiography, coronary disease, ischemia | Circ Popul Health Outcomes | 2026 | 0 |
| Standard modifiable cardiovascular risk factors and acute coronary syndrome free survival. PMID 42297539 — diabetes mellitus, bias, hypertension, mortality, acute coronary syndrome, risk factors, heart disease risk factors, smoking, hypercholesterolemia | Atherosclerosis | 2026 | 0 |
| The Paradox of SMURF-less Outcomes and its Implication for Diabetes. PMID 41606783 — diabetes mellitus, mortality, cardiovascular diseases, acute coronary syndrome, clinical medicine, coronary disease, risk factors | Eur Heart J Qual Care Clin Outcomes | 2026 | 0 |
| Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial. PMID 41520674 — diabetes mellitus, stents, coronary artery disease, myocardial infarction, pharmaceutical preparations, sirolimus, arteries, everolimus, therapeutics | Lancet Top journal | 2026 | 0 |
| Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold. PMID 40996403 — stents, cardiovascular diseases, percutaneous coronary intervention, acute coronary syndrome, tomography, optical coherence, therapeutics, thrombosis | JACC Case Rep | 2025 | 0 |
Clinical Studies 23
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| IVI guided Versus Angiography guided PCI in Patients With Diabetes Mellitus NCT06380868 — diabetes mellitus, stents, drug-eluting stents, pharmaceutical preparations, tomography, angiography, tomography, optical coherence | N/A | Recruiting | 2024 |
| International Survey of Acute Coronavirus Syndromes COVID 19 NCT05188612 — registries, coronavirus, biomedical research, covid-19, research | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map